Crestor (Rosuvastatin) and Hormonal Contraceptives: Drug Interaction Guide

What the Interaction Looks Like Pharmacokinetically

Co-administration of rosuvastatin 40 mg with an oral contraceptive containing ethinyl estradiol 0.035 mg and norgestrel 0.180 mg increased the AUC of ethinyl estradiol by 26% and norgestrel by 34% in healthy female volunteers. These figures come directly from the FDA-approved Crestor prescribing information [1].

The direction of this interaction matters. Rosuvastatin increases the hormone levels, not the other way around. Oral contraceptive co-administration does not meaningfully alter rosuvastatin plasma concentrations or its lipid-lowering efficacy. This is a one-directional pharmacokinetic effect.

Unlike atorvastatin and lovastatin, which undergo extensive CYP3A4 metabolism, rosuvastatin is minimally metabolized by the cytochrome P450 system. Fewer than 10% of rosuvastatin molecules pass through CYP2C9, and it has negligible affinity for CYP3A4 [2]. The mechanism behind the hormone-level increase is not fully characterized but likely involves competition at hepatic uptake transporters, specifically organic anion-transporting polypeptide 1B1 (OATP1B1) and breast cancer resistance protein (BCRP), both of which participate in the hepatic clearance of ethinyl estradiol and steroid hormones [3].

A 26% rise in ethinyl estradiol exposure sits in a range that most women tolerate without clinical consequence. For context, switching between branded and generic oral contraceptives commonly produces AUC variability of 20% or more under standard bioequivalence criteria. The increase does not reduce contraceptive efficacy. If anything, higher hormone levels reinforce ovulation suppression.

Clinical Severity: What Drug Interaction Databases Say

Most prescribers will see a "monitor" or "minor" flag. The interaction does not carry a "contraindicated" or "serious" designation in any major reference database.

Lexicomp classifies the rosuvastatin-oral contraceptive interaction as severity rating C ("monitor therapy"), indicating that the combination can be used with appropriate surveillance but no mandatory dose modification [4]. Micromedex assigns it a "moderate" interaction rating, defined as one that may require a change in therapy under specific clinical circumstances. The UpToDate drug interaction checker references the same PK data from the Crestor label and notes that routine monitoring for estrogen-excess symptoms is reasonable [5].

No case reports in the published literature describe a thromboembolic event, breakthrough bleeding pattern, or contraceptive failure directly attributed to this drug pair. That absence does not prove absolute safety, but it does reflect decades of real-world co-prescribing. Rosuvastatin received FDA approval in 2003, and combined oral contraceptives remain the most commonly prescribed reversible contraceptive method in the United States, used by approximately 6.5 million women aged 15 to 49 according to the CDC [6].

Why This Combination Gets Prescribed Together

Statins and hormonal contraceptives share a patient population more often than many clinicians realize. Women of reproductive age diagnosed with familial hypercholesterolemia (FH) represent the most common scenario.

Heterozygous FH affects roughly 1 in 250 individuals worldwide, per data from the European Atherosclerosis Society [7]. Women with this diagnosis often begin statin therapy in their twenties, precisely when reliable contraception is both desired and medically important. All statins carry an FDA contraindication in pregnancy due to theoretical risk to fetal development. The FDA label for rosuvastatin states: "Crestor is contraindicated in women who are pregnant or may become pregnant. Because statins decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, CRESTOR may cause fetal harm" [1].

This creates a clinical imperative: women on rosuvastatin who are sexually active and do not desire pregnancy need effective contraception. The combination is not accidental but medically necessary. Telling a patient to avoid oral contraceptives solely because of a 26% increase in ethinyl estradiol exposure would leave her with fewer contraceptive options and no statin alternative free of the same pregnancy contraindication.

Dose-by-Dose Breakdown: Does the Rosuvastatin Dose Matter?

The PK interaction study in the Crestor label used 40 mg, which is the maximum approved dose. Lower doses (5 mg, 10 mg, 20 mg) have not been studied in formal interaction trials with oral contraceptives, but pharmacologic reasoning supports a dose-proportional or lesser effect.

Rosuvastatin exhibits linear pharmacokinetics across the 5 to 40 mg dose range, as demonstrated in single- and multiple-dose studies submitted to the FDA [1]. If competition at OATP1B1/BCRP transporters drives the hormone-level increase, the effect at 10 mg (the most commonly prescribed dose in the United States) would likely be smaller than the 26%/34% figures observed at 40 mg.

The clinical takeaway is straightforward. The labeled interaction data represent a worst-case scenario at the highest approved dose. Most patients take 10 or 20 mg. No dose adjustment of either drug is recommended at any rosuvastatin dose.

| Rosuvastatin dose | Expected EE interaction | Dose adjustment needed | |---|---|---| | 5 mg | Likely <26% AUC increase | No | | 10 mg | Likely <26% AUC increase | No | | 20 mg | Approaching labeled values | No | | 40 mg | ~26% EE / ~34% norgestrel AUC increase | No |

How This Compares to Other Statin-Contraceptive Interactions

Rosuvastatin is not unique here. Atorvastatin co-administration increases ethinyl estradiol AUC by approximately 20% and norethindrone AUC by approximately 30%, per the Lipitor prescribing information [8]. The magnitude is similar.

The key differentiator is the mechanism. Atorvastatin's interaction with oral contraceptives involves CYP3A4, since both atorvastatin and ethinyl estradiol are CYP3A4 substrates. Rosuvastatin bypasses CYP3A4 almost entirely, which means adding a CYP3A4 inhibitor (like clarithromycin or grapefruit juice) would compound the atorvastatin-OC interaction but would not affect the rosuvastatin-OC interaction.

Pravastatin and pitavastatin have the least interaction data with oral contraceptives but share rosuvastatin's minimal CYP metabolism. Simvastatin, a CYP3A4 substrate like atorvastatin, has not been formally studied with oral contraceptives in published PK trials, though the interaction is expected to follow similar patterns.

For women on multiple CYP3A4-interacting medications, rosuvastatin may actually be a safer statin choice precisely because its interaction with oral contraceptives does not stack with other CYP3A4 inhibitors in the medication list [2].

What About Non-Oral Hormonal Contraceptives?

The published interaction data apply specifically to combined oral contraceptives. No formal PK studies have evaluated rosuvastatin with transdermal patches (Xulane), vaginal rings (NuvaRing/Annovera), hormonal IUDs (Mirena, Liletta), etonogestrel implants (Nexplanon), or depot medroxyprogesterone acetate (Depo-Provera).

The interaction mechanism matters here. Transdermal and vaginal ring delivery systems bypass first-pass hepatic metabolism, which means the hormone reaches systemic circulation before encountering hepatic uptake transporters. If the rosuvastatin interaction occurs at the level of hepatic OATP1B1 transporters during first-pass processing, non-oral routes might be less affected. This is plausible but unproven.

Progestin-only methods (hormonal IUD, implant, Depo-Provera) do not contain ethinyl estradiol. Since the labeled interaction specifically measured ethinyl estradiol and norgestrel changes, progestin-only methods may have a different interaction profile. The levonorgestrel IUD releases hormone locally in the uterus with minimal systemic absorption (blood levels approximately 150 to 200 pg/mL), making a clinically meaningful transporter-level interaction unlikely [9].

For patients concerned about this interaction, a hormonal IUD or implant sidesteps the question entirely while providing superior contraceptive efficacy (failure rates <1% vs. 7% to 9% typical-use failure for oral contraceptives, per the CDC contraceptive guidance) [10].

Monitoring Recommendations

Providers should counsel patients about estrogen-excess symptoms at the time of co-prescribing and during follow-up visits. No routine lab monitoring is needed specifically for this interaction.

Signs that warrant clinical attention include new or worsening headaches (particularly migraines with aura), breast tenderness that was not present before statin initiation, nausea, or changes in menstrual flow patterns. A 2014 review in Contraception noted that estrogen-dose-dependent side effects generally follow a threshold pattern rather than a linear one, meaning many women will tolerate a 26% AUC increase without symptoms while others near their individual threshold may notice changes [11].

The lipid panel schedule does not change. Standard monitoring (fasting lipid panel at baseline, 4 to 12 weeks after initiation, then annually) applies regardless of contraceptive co-administration. Oral contraceptives themselves can raise triglycerides by 30% to 50% in some women, according to a 2020 analysis in the Journal of Clinical Endocrinology & Metabolism, which may confound interpretation of rosuvastatin's triglyceride-lowering effect [12].

If triglycerides rise unexpectedly in a woman taking both medications, the oral contraceptive's own effect on triglyceride synthesis should be considered before escalating the statin dose.

When to Consider Switching

Switching away from rosuvastatin is rarely necessary based on this interaction alone. Three scenarios warrant reconsideration.

Scenario 1: Estrogen-excess side effects emerge after statin initiation. If a patient develops breast tenderness, worsened migraines, or significant mood changes temporally related to rosuvastatin addition, consider switching to a lower-EE oral contraceptive (20 mcg ethinyl estradiol formulations) rather than changing the statin. The interaction amplifies whatever estrogen dose is present, so lowering the base dose reduces the absolute increase.

Scenario 2: The patient has VTE risk factors. Women with obesity (BMI >30), Factor V Leiden, age over 35 who smoke, or a personal history of venous thromboembolism are already at elevated estrogen-related clotting risk. Adding a drug that raises estrogen levels, even modestly, may tip the risk-benefit calculus. The American College of Obstetricians and Gynecologists practice bulletin on hormonal contraception recommends against combined hormonal contraceptives in women with multiple VTE risk factors regardless of statin use [13]. In these patients, progestin-only or non-hormonal contraception is preferred.

Scenario 3: The patient takes other drugs that increase estrogen levels. If the medication list includes another agent known to raise ethinyl estradiol exposure (e.g., certain antiretrovirals or antifungals), the cumulative effect with rosuvastatin could push the total estrogen increase beyond the 30% to 40% range. Review the full medication list for stacking interactions.

Patient Counseling Points

Five items belong in every counseling conversation when prescribing this combination.

First, contraceptive efficacy is not reduced. Patients sometimes hear "drug interaction" and assume their birth control will fail. The opposite is true here: hormone levels go up, not down.

Second, the interaction was measured at the highest Crestor dose (40 mg). Most patients take 10 or 20 mg, where the effect is likely smaller.

Third, report new headaches, breast pain, or unusual menstrual patterns. These may signal that the estrogen increase is clinically relevant for that individual.

Fourth, pregnancy must be avoided while on any statin. If the patient plans to discontinue her oral contraceptive, she should inform her prescriber so statin therapy can be paused if she might become pregnant.

Fifth, long-acting reversible contraceptives (IUDs, implants) are not affected by this interaction and provide higher efficacy rates. Women who want to eliminate this pharmacokinetic concern entirely can switch methods without changing their statin.